sulforaphane has been researched along with Cytokine Release Syndrome in 1 studies
sulforaphane: from Cardaria draba L.
sulforaphane : An isothiocyanate having a 4-(methylsulfinyl)butyl group attached to the nitrogen.
Cytokine Release Syndrome: A severe immune reaction characterized by excessive release of CYTOKINES. Symptoms include DYSPNEA; FEVER; HEADACHE; HYPOTENSION; NAUSEA; RASH; TACHYCARDIA; HYPOXIA; HYPERFERRITINEMIA, and MULTIPLE ORGAN FAILURE. It is associated with viral infections, SEPSIS; AUTOIMMUNE DISEASES and a variety of factors used in IMMUNOTHERAPY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The "cytokine storm" is associated with severe forms of COVID-19 and poor prognosis for COVID-19 patients." | 1.62 | Sulforaphane inhibits the expression of interleukin-6 and interleukin-8 induced in bronchial epithelial IB3-1 cells by exposure to the SARS-CoV-2 Spike protein. ( Borgatti, M; D'Aversa, E; Finotti, A; Gambari, L; Gambari, R; Gasparello, J; Grigolo, B; Papi, C, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gasparello, J | 1 |
| D'Aversa, E | 1 |
| Papi, C | 1 |
| Gambari, L | 1 |
| Grigolo, B | 1 |
| Borgatti, M | 1 |
| Finotti, A | 1 |
| Gambari, R | 1 |
1 other study available for sulforaphane and Cytokine Release Syndrome
| Article | Year |
|---|---|
Sulforaphane inhibits the expression of interleukin-6 and interleukin-8 induced in bronchial epithelial IB3-1 cells by exposure to the SARS-CoV-2 Spike protein.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Bronchi; Cell Line; Chemokines; COVID-19; Cytoki | 2021 |